News & Events

• September 1, 2022
  

  C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Lysosomal Diseases

  C-Path today announced the launch of a pre-consortium collaboration focused on accelerating medical product development in lysosomal diseases, supported by a grant from the U.S. Food and Drug Administration (FDA).

• August 25, 2022
  

  Upcoming Rare Disease Workshop Focuses on the Importance of Data Sharing in Drug Development

  C-Path, NORD and FDA to host annual workshop September 13-14 to highlight the impact of their innovative data and analytics platform on rare disease drug development   TUCSON, Ariz. and WASHINGTON, DC, August 25, 2022 — The Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP®) will host its in-person annual workshop on September 13...
• September 30, 2021
  

  C-Path and Pulse Infoframe Establish Patient-Centered Data Harmonization Partnership to Accelerate Collaborative Research in Rare Disease

  Critical Path Institute (C-Path) and Pulse Infoframe announced today their collaboration to advance technologies and tools to further rare disease research and drug development. In addition, both organizations will support the creation of more streamlined and transparent informed consent processes and best practices for the development of global unique identifiers, data standards and data dictionaries.

• September 15, 2021
  

  Rare Disease Innovation and Data Sharing Accelerated by New RDCA-DAP Program

  The Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP^®) officially launched its next phase on Tuesday establishing itself as the leading platform to accelerate rare disease treatment innovation. The launch was part of an all-day virtual workshop and annual meeting of rare disease stakeholders, featuring a platform demonstration, industry expert presentations and attendance by over 400 patients, providers, researchers, clinicians, biopharmaceutical companies, regulatory reviewers and scientists.

• July 15, 2021
  

  Launch of UNITE4TB Partnership Marks a New Era in Tuberculosis Treatment Development

  To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions for TB patients worldwide, a new consortium of 30 partners from 13 countries has officially launched. The 7-year, €185 million project called UNITE4TB, aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active TB treatment regimens for drug-resistant and -sensitive TB.